Frost Radar™: Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022

Frost Radar™: Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022

A Benchmarking System to Spark Companies to Action-Innovation that Fuels New Deal Flow and Growth Pipelines

RELEASE DATE
16-Nov-2022
REGION
North America
Research Code: PDD4-01-00-00-00
SKU: HC03603-NA-MR_27123
AvailableYesPDF Download

$4,950.00

Special Price $4,455.00 save 10 %

In stock
SKU
HC03603-NA-MR_27123

$4,950.00

$4,455.00save 10 %

DownloadLink
ENQUIRE NOW

Description

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treatment. Some organizations double up as hybrid CDMOs and incubators.
They have their own pipelines, but they also partner with other companies to support and accelerate development.

Contract development and manufacturing organizations (CDMOs) and CROs are expanding organically and inorganically to provide end-to-end CGT services. More than 100 companies compete in the CGT CDMO marketplace globally, and most specialize in either cell therapy or gene therapy. Only a handful offer diversified services. CDMOs are increasingly distinguishing themselves from their competitors and have redefined themselves as contract research, development, and manufacturing organizations (CRDMOs) and have integrated themselves into companies’
value chains.

The Frost Radar™ reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the
Frost Radar™ methodology. The document presents competitive profiles on each of the companies in the Frost Radar™ based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in an industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned.

Author: Surbhi Gupta

Table of Contents

Strategic Imperative

Growth Environment

Growth Environment (continued)

Frost Radar™: Cell and Gene Therapy CDMOs

Frost Radar™: Competitive Environment

Frost Radar™: Competitive Environment (continued)

AGC Biologics

Catalent

Charles River Laboratories

Lonza

Merck KGaA

Minaris Regenerative Medicine

RoslinCT

Thermo Fisher Scientific

WuXi Advanced Therapies

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treatment. Some organizations double up as hybrid CDMOs and incubators. They have their own pipelines, but they also partner with other companies to support and accelerate development. Contract development and manufacturing organizations (CDMOs) and CROs are expanding organically and inorganically to provide end-to-end CGT services. More than 100 companies compete in the CGT CDMO marketplace globally, and most specialize in either cell therapy or gene therapy. Only a handful offer diversified services. CDMOs are increasingly distinguishing themselves from their competitors and have redefined themselves as contract research, development, and manufacturing organizations (CRDMOs) and have integrated themselves into companies’ value chains. The Frost Radar™ reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar™ methodology. The document presents competitive profiles on each of the companies in the Frost Radar™ based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in an industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned. Author: Surbhi Gupta
More Information
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number PDD4-01-00-00-00